Suppr超能文献

中药成分ON-III(2',4'-二羟基-6'-甲氧基-3',5'-二甲基查尔酮)对血管内皮生长因子受体信号通路的阻断及抗肿瘤活性

Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine.

作者信息

Zhu Xiao-Feng, Xie Bin-Fen, Zhou Jun-Min, Feng Gong-Kan, Liu Zong-Chao, Wei Xiao-Yi, Zhang Feng-Xian, Liu Mei-Fang, Zeng Yi-Xin

机构信息

Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou, China.

出版信息

Mol Pharmacol. 2005 May;67(5):1444-50. doi: 10.1124/mol.104.009894. Epub 2005 Feb 9.

Abstract

Antiangiogenesis is a promising strategy of cancer treatment. Vascular endothelial growth factor receptor [fetal liver kinase/kinase-inserting domain-containing receptor (KDR)] is a tyrosine kinase receptor and has been strongly implicated in tumor angiogenesis. In this study, we report that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (ON-III), extracted from the dried flower Cleistocalyx operculatus, used in traditional Chinese medicine, reversibly inhibited KDR tyrosine kinase phosphorylation, but epidermal growth factor receptor tyrosine kinase phosphorylation was unaffected under the same concentrations of ON-III. ON-III also inhibited mitogen-activated protein kinase (MAPK) and AKT activation of KDR signal transduction in downstream molecules without reduced total MAPK and AKT. The results in vitro showed that ON-III inhibited growth of human vascular endothelial HDMEC cells in the presence of VEGF preferentially, compared with epidermal growth factor. Systemic administration of ON-III at nontoxic doses in nude mice resulted in inhibition of subcutaneous tumor growth of human hepatocarcinoma Bel7402 and lung cancer GLC-82 xenografts. The tumor vessel density decreased, as determined by immunohistochemical staining, for CD31 after ON-III treatment. These results indicated that ON-III inhibited KDR tyrosine kinase, shut down KDR-mediated signal transduction, and inhibited tumor growth of human xenografts in vivo.

摘要

抗血管生成是一种很有前景的癌症治疗策略。血管内皮生长因子受体[胎儿肝激酶/含激酶插入结构域受体(KDR)]是一种酪氨酸激酶受体,与肿瘤血管生成密切相关。在本研究中,我们报告从传统中药水翁干花中提取的2',4'-二羟基-6'-甲氧基-3',5'-二甲基查耳酮(ON-III)可逆性抑制KDR酪氨酸激酶磷酸化,但在相同浓度的ON-III作用下,表皮生长因子受体酪氨酸激酶磷酸化未受影响。ON-III还抑制有丝分裂原激活蛋白激酶(MAPK)和AKT在KDR信号转导下游分子中的激活,而不降低总MAPK和AKT水平。体外实验结果表明,与表皮生长因子相比,ON-III在有VEGF存在的情况下优先抑制人血管内皮HDMEC细胞的生长。以无毒剂量对裸鼠进行ON-III全身给药,可抑制人肝癌Bel7402和肺癌GLC-82异种移植瘤的皮下肿瘤生长。经免疫组织化学染色测定,ON-III治疗后肿瘤血管密度降低,CD31表达减少。这些结果表明,ON-III抑制KDR酪氨酸激酶,阻断KDR介导的信号转导,并在体内抑制人异种移植瘤的生长。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验